Category: Company
Quick infos Trade prices Volume: Market Cap: 675.95M Prev closed: 18.65 Open: 18.85 High: 19.27 Low: 18.66 52 week low: 7.32 52 week high: 21.97 Dividends: No Dividends Next ER: November 5, 2020 After Market Closes
About the Company Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris and New York City.
Earnings History Date EPS / Forecast Revenue / Forecast March 2, 2021 November 5, 2020 -0.71 / -0.619.24M / 10.36MAugust 5, 2020 -0.76 / -0.742.9M / 4.58MBeat! May 6, 2020 0.47 / -0.6451.91M / 16.23MBeat! March 16, 2020 - / -0.74- / 4.97Mview more
Historical Data Date Price Open High Low Vol Change ER Jan 14, 2021 31.69 29.80 31.84
29.80
174.44K 8.30% Jan 13, 2021 29.26 28.40 31.16
28.24
426.08K 4.99% Jan 12, 2021 27.87 27.63 28.13
27.52
263.71K 1.20% Jan 11, 2021 27.54 28.65 28.98
27.47
384.82K -6.9% Jan 8, 2021 29.58 29.57 31.43
29.50
673.15K 2.18% Jan 7, 2021 28.95 27.48 29.56
27.48
451.77K 6.71% Jan 6, 2021 27.13 27.05 28.95
27.05
449.14K -0.18% Jan 5, 2021 27.18 27.97 28.04
26.46
276.54K -1.52% Jan 4, 2021 27.60 28.02 28.56
26.96
347.85K 2% Dec 31, 2020 27.06 29.45 29.45
26.58
394.62K -7.99% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company Founded:1999 Employees:122 News
Cellectis EPS misses by $0.02, misses on revenue seekingalpha.com Aug 6, 2020 4:40 am
Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2020 finance.yahoo.com Aug 5, 2020 4:30 pm
Cellectis Reports Clinical Hold Placed on MELANI-01 Study finance.yahoo.com Aug 4, 2020 4:33 pm
Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development finance.yahoo.com Aug 4, 2020 4:30 pm Biotech IPO Nkarta triples in debut seekingalpha.com Jul 11, 2020 12:45 am Cellectis under pressure on safety signal in multiple myeloma study seekingalpha.com Jul 7, 2020 5:15 am
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing finance.yahoo.com Aug 4, 2020 4:30 pm
Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products finance.yahoo.com Aug 4, 2020 4:05 pm
Top Ranked Momentum Stocks to Buy for May 12th finance.yahoo.com Aug 4, 2020 10:02 am
Wired News - Atara Biotherapeutics Expands T-Cell Immunotherapy Collaboration with MSK to Develop Next-Generation CAR T Technologies finance.yahoo.com Aug 4, 2020 7:30 am
Harvards Wyss Institute Partners with Cellectis to Recode the Human Genome finance.yahoo.com Aug 4, 2020 7:00 am
Cellectis to Present Data at the 2018 AACR Annual Meeting finance.yahoo.com Aug 4, 2020 1:50 am
Cellectis to Hold Second Quarter 2020 Earnings Call on Thursday, August 6, 2020 at 7:30AM EDT finance.yahoo.com Jul 29, 2020 4:30 pm
Cellectis Appoints Biopharma Veteran Steve Doares, Ph.D., as Senior Vice President of US Manufacturing finance.yahoo.com Jul 21, 2020 4:30 pm
Monthly information on share capital and company voting rights finance.yahoo.com Jul 10, 2020 6:04 pm
The Daily Biotech Pulse: Novavax Lands $1.6B For COVID-19 Vaccine, Amgen Prevails In Avastin Biosimilar Lawsuit, Cellectis Study Placed On Clinical Hold finance.yahoo.com Jul 7, 2020 8:17 am
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxts Board of Directors finance.yahoo.com Jul 6, 2020 5:19 pm
Cellectis SA (CLLS): Hedge Funds Are Snapping Up finance.yahoo.com Jul 5, 2020 10:28 pm
Is Cellectis (CLLS) Outperforming Other Medical Stocks This Year? finance.yahoo.com Jun 30, 2020 11:30 am
Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 29, 2020 finance.yahoo.com Jun 29, 2020 4:30 pm This company doesn't provide a dividend.
Key Persons CEO : André Choulika, PhD Talk about Cellectis SA below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature. Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus BUY 100 HOLD 0 SELL 0
If you want to help pay for server cost or for improving this tool. You can send it via Paypal . More features coming soon :)
Buy on Amazon Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis